Overview

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation. Key secondary objectives included: 1. The proportion of subjects who were nausea free at two hours after patch activation. 2. The proportion of subjects who were photophobia free at two hours after patch activation. 3. The proportion of subjects who were phonophobia free at two hours after patch activation.
Phase:
Phase 3
Details
Lead Sponsor:
NuPathe Inc.
Treatments:
Sumatriptan